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Insulin resistance is a metabolic disorder associated with type 2 diabetes.
Recent reports have shown that fibroblast growth factor-21 (FGF-21)
plays an important role in the progression of insulin resistance. However,
the biochemical and molecular mechanisms by which changes in FGF-21
activation result in changes in the rates of hepatic gluconeogenesis and
glycogenolysis remain to be elucidated. In this study, we developed ade-
novirus-mediated shRNA against FGF-21 to inhibit FGF-21 expression
in ApoE knockout mice. Using this mouse model, we determined the
effects of FGF-21 knockdown in vivo on hepatic glucose production, glu-
coneogenesis and glycogenolysis, and their relationship with the signal
transducer and activator of transcription 3 (STAT3)/suppressor of cyto-
kine signaling 3 (SOCS3) signal pathways. We show that liver-specific
knockdown of FGF-21 in high-fat diet-fed ApoE knockout mice resulted
in a 39% increase in glycogenolysis and a 75% increase in gluconeogene-
sis, accompanied by increased hepatic expression of glucose-6-phosphatase
and phosphoenolpyruvate carboxykinase. Furthermore, FGF-21 knock-
down decreased phosphorylation of STAT3 and SOCS3 expression in
high-fat diet-fed mice. Our data suggest that hepatic FGF-21 knockdown
increases gluconeogenesis and glycogenolysis by activation of glucose-6-
phosphatase and phosphoenolpyruvate carboxykinase via the STAT3/
SOCS3 pathway, ultimately leading to exacerbation of hepatic insulin
resistance.
Introduction
Fibroblast growth factor-21 (FGF-21) is a recently
identified member of the FGF family, and is
preferentially expressed in the liver [1]. We previously
demonstrated that plasma FGF-21 levels are elevated
in patients with type 2 diabetes and patients with dia-
betic ketoacidosis [1,2], and decreased in response to
rosiglitazone treatment [3]. In fact, in both diet-
induced obese mice [4] and genetically obese ob/ob
mice, FGF-21 plasma levels and expression in white
adipose tissue and liver are increased [5]. It is
therefore believed that FGF-21 resistance occurs in
obesity and diabetes [6]. In obese and diabetic
rodents, treatment with pharmacological doses of
FGF-21 reduced body fat and improved glucose
tolerance, insulin sensitivity and lipid levels [7–11].
Nevertheless, the physiological roles of FGF-21 in the
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development of insulin resistance remain to be estab-
lished. In the present study, we have developed an
adenovirus-mediated RNAi technique in which shR-
NA against FGF-21 were used to inhibit FGF-21
expression in vivo. The major advantages of shRNA
silencing of gene expression in a normal adult animal
are its efficiency and specificity, avoiding the con-
founding compensatory developmental effects often
associated with gene knockout mouse models.
It has been recognized that lipid disorders are the
earliest events in development of insulin resistance and
type 2 diabetes [12]. ApoE knockout (KO) mice
develop severe atherosclerosis and hypercholesterol-
emia on a standard chow diet (SCD), and are widely
used as a model of insulin resistance when fed with
high-fat diet (HFD) [13]. HFD-fed ApoE KO mice are
also a useful model for studying the lipid disorders
and insulin resistance associated with increased tissue
expression and plasma levels of FGF-21 [14,15].
Type 2 diabetes and insulin resis-tance are believed to
arise from a combination of genetic and environmental
factors. Therefore, this mouse model, in which insulin
resistance is developed by feeding an HFD (environ-
mental factor) to ApoE KO mice (genetic factor), clo-
sely simulates human insulin resistance conditions, and
was used to determine the effect of elevation of circu-
lating FGF-21 on the onset of insulin resistance.
Recent studies have shown that the signal transducer
and activator of transcription 3 (STAT3)/suppressor
of cytokine signaling 3 (SOCS3) pathway regulates
signal transduction of many factors related to insulin
sensitivity and glucose metabolism [16,17]. As FGF-21
is a metabolic regulator, it is important to determine
whether the STAT3/SOCS3 pathway is involved in the
metabolic effects of FGF-21. In this study, we exam-
ined the effect of FGF-21 knockdown on the relative
contribution of gluconeogenesis and glycogenolysis to
the glucose-6-phosphatase (G6Pase) flux and the
STAT3/SOCS3 pathway using adenovirus-mediated
shRNA of FGF-21 in HFD-fed mice.
Results
RNAi-mediated FGF-21 knockdown decreased
hepatic expression and plasma levels of FGF-21
A previously validated shRNA sequence against
FGF-21[18] was introduced into an adenovirus vector
(Ad-shFGF-21), and its relatively silencing efficiency
was compared with that of a control sequence (Ad-
shGFP). Treatment with Ad-shFGF-21 achieved 43%
and 50% reductions in the levels of FGF-21 mRNA and
protein in the liver (P < 0.01, Fig. 1A,C) but no reduc-
tion was observed in muscle (Fig. S1). When compared
with HFD-fed ApoE KO mice (HF group) and HFD-
fed plus Ad-shGFP-treated ApoE KO mice (GFP
group), HFD-fed plus Ad-shFGF-21 treated mice (HFG
group) showed a 30% reduction in the plasma FGF-21
levels (P < 0.01, Fig. 1B), demonstrating that Ad-
shFGF-21 effectively reduces FGF-21 expression in vivo.
Effect of RNAi-mediated FGF-21 knockdown on
metabolic parameters
We next assessed the effects of FGF-21 knockdown on
metabolic parameters. Values for body weight and
many plasma parameters, including fasting blood glu-
cose, lipids, insulin and hepatic triglycerides (TG),
were significantly higher in ApoE KO mice fed the
HFD than in their littermates fed a standard chow diet
(SCD) (NF group) (P < 0.05 or P < 0.01, Table 1).
There were no significant differences in fasting blood
glucose, total cholesterol (TC), low-density lipoprotein
cholesterol (LDL-C), high-density lipoprotein choles-
terol (HDL-C), free fatty acids (FFA), or insulin and
hepatic TG between the HF and GFP groups. How-
ever, the plasma levels of fasting blood glucose, TC,
LDL-C, FFA, insulin and hepatic TG in the HFG
group were significantly higher than in the HF and
GFP groups (P < 0.05 or P < 0.01, Table 1); the
HDL-C level was significantly lower (P < 0.05).
Effect of RNAi-mediated FGF-21 knockdown on
glucose homeostasis and insulin sensitivity
To assess the effects of FGF-21 knockdown on glucose
homeostasis and insulin action in HFD-induced insulin
resistance, we performed euglycemic/hyperinsulinemic
clamp studies in the four experimental groups (Fig. 2A,
B). Plasma glucose was clamped at ~ 6 mM in all groups
(Fig. S2A), whereas plasma insulin levels were increased
approximately four- to sixfold compared with basal val-
ues. Despite identical insulin infusion rates
(5 mUkg1min1), plasma insulin levels during the
clamps were higher in the HFG group than in the other
groups (P < 0.01, Fig. 2C). TG, TC and FFA levels
were suppressed by hyperinsulinemia in all animals
(P < 0.01), but remained significantly higher in the
HFG group (P < 0.05 or P < 0.01, Fig. 2D–F). Fig-
ure 3A shows the glucose infusion rates required to
maintain euglycemia in the various groups. The glucose
infusion rate was decreased by ~ 76% in mice fed the
HFD (HF group) compared with mice fed the SCD (NF
group, P < 0.01). However, the glucose infusion rate
(GIR) was significantly decreased in the HFG group
compared with the GFP group (P < 0.01), indicating
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increased whole-body insulin resistance. The rate of glu-
cose disappearance in HFD-fed mice (HF group) was
lower than that in SCD-fed mice (NF group, ~ 80%,
P < 0.01), and administration of HFD plus Ad-shFGF-
21 in the HFG group resulted in a further 5% decrease
in the rate of disappearance of glucose compared with
that in the GFP group (P < 0.05, Fig. 3B). As expected,
suppression of hepatic glucose production (HGP) by
hyperinsulinemia was almost 70% in the NF group
(14.2  0.3 versus 4.3  2.3 mgkg1min1, Fig. 3C),
Table 1. Characteristics of the experimental groups.
NF HF GFP HFG
Body weight (g) 27.4  1.2 29.4  1.3** 28.5  1.2** 28.7  1.5**
FBG (mM) 5.9  0.8 7.7  0.8** 7.7  0.4** 8.4  0.5**,†,§
Fasting insulin
(mUL1)
82.3  6.3 111.2  13.0** 112.1  13.6** 133.1  10.4**,‡,§§
TC (mM) 12.2  3.1 21.9  1.8** 20.9  2.4** 24.8  2.06**,†,§
TG (mM) 1.2  0.2 2.3  0.2** 2.2  0.2** 2.6  0.2**,‡,§§
FFA (mM) 2.21  0.34 3.1  0.09** 3.10  0.10** 3.5  0.10**,‡,§§
HDL-C (mM) 2.5  0.5 4.6  0.8** 4.5  0.5** 3.9  0.3**,‡,§§
LDL-C (mM) 6.0  1.7 14.0  2.1** 13.7  2.2** 16.6  1.5**,‡,§§
Hepatic TG
(mgg1 liver)
14.5  2.3 39.2  3.04** 41.0  3.27** 46.1  3.71**,†,§
Hepatic glycogen
(mgg1 liver)
22.4  3.13 16.1  1.92** 15.9  1.37** 13.8  1.1**,†,§
FBG, fasting blood glucose; TC, total cholesterol; TG, triglycerides; FFA, free fatty acids; HDL-C, high density lipoprotein cholesterol; LDL-C,
low density lipoprotein cholesterol; NF, SCD-fed mice; HF, HFD-fed ApoE KO mice; GFP, HFD-fed ApoE KO mice treated with Ad-shGFP;
HFG, HFD-fed ApoE KO mice treated with Ad-shFGF-21. Values are means  SE.
**P < 0.01 versus the NF group; †P < 0.05, ‡P < 0.01 versus the HF group; §P < 0.05, §§P < 0.01 versus the GFP group.
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C Fig. 1. Adenovirus-mediated FGF-21
knockdown in HFD-fed ApoE KO mice.
Mice were injected with Ad-shFGF-21 or
Ad-shGFP (1 9 109 plaque-forming units
g1 body weight) as described in the text.
(A) Relative FGF-21 mRNA levels in the
liver. (B) Plasma FGF-21 levels. (C) FGF-21
protein level in the liver. All data are the
results of at least five independent
experiments. NF, SCD-fed mice; HF, HFD-
fed ApoE KO mice; GFP, HFD-fed ApoE
KO mice treated with Ad-shGFP; HFG,
HFD-fed ApoE KO mice treated with Ad-
shFGF-21. Values are means  SE, and
are expressed as fold changes relative to
the levels in the NF group.
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but only ~ 51% in the HF group (16.2  0.3 versus
8.0  5.5 mgkg1min1). Importantly, in the HFG
group, HGP was suppressed by only 20% (from
18.0  1.1 to 14.4  2.4 mgkg1min1), indicating a
marked increase in hepatic insulin resistance. The insu-
lin action on glucose production was expressed as a per-
centage suppression of the basal levels (Fig. 3D). In
addition, the GIR to insulin during the clamp was low-
est in the HFG group, suggesting more serious insulin
resistance in peripheral tissues of these animals
(P < 0.05 or P < 0.01, Fig. 3E). The rate of glucose dis-
appearance calculated on the basis of [3-3H] glucose
radioactivity levels is shown in Fig. S2.
Mechanisms by which FGF-21 knockdown
increases glucose production
To determine the mechanism by which FGF-21 knock-
down modulates liver glucose homeostasis, we exam-
ined the in vivo glucose flux through G6Pase and the
relative contribution of glucose cycling to G6Pase flux.
As shown in Fig. 4A,B, compared to SCD feeding (NF
group), HFD feeding in the HF group increased the
flux through G6Pase by 36% (from 7.8  1.1 to
10.6  1.3 mgkg1min1; P < 0.01) and glucose
cycling by 45% (from 2.2  0.3 to 3.2  0.5
mgkg1min1; P < 0.01). FGF-21 knockdown in the
HFG group further increased the G6Pase flux by 32%
(from 10.6  1.3 to 13.8  1.0 mgkg1min1,
P < 0.05) and glucose cycling by 28% (from 3.2  0.5
to 4.1  0.6 mgkg1min1, P < 0.05, Fig. 4A,B), sug-
gesting that FGF-21 knockdown increased the activity
of G6Pase in the livers of HFD mice. We next exam-
ined the effect of FGF-21 knockdown on the relative
contribution of glycogenolysis and gluconeogenesis to
G6Pase flux. The effects of HFD feeding on glucose
production and G6Pase flux in mice were accounted
by a 25% increase in the rate of glycogenolysis
(2.0  0.5 mgkg1min1 in the HF group versus
1.3  0.4 mgkg1min1 in the NF group, P < 0.05)
and a 75% increase in the rate of gluconeogenesis
(6.0  1.6 mgkg1min1 in the HF group versus
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Fig. 2. Steady-state plasma parameters
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3.0  0.6 mgkgmin1 in the NF group, P < 0.01). In
the HFG group, the increase in HGP by FGF-21
knockdown was accounted for by a 39% increase in
the rate of glycogenolysis (5.6  1.1 mgkg1min1)
and a 61% increase in the rate of gluconeogenesis
(8.8  1.2 mgkg1min1) (Fig. 4C,D). Furthermore,
hepatic glycogen in the HFG group was significantly
higher than that in the HF and GFP groups (P < 0.05,
Table 1).
In agreement with changes in glucose metabolism,
the FGF-21 knockdown in the HFG group signifi-
cantly increased hepatic G6Pase mRNA and protein
expression compared with in other three groups
(Fig. 5A,C). Moreover, FGF-21 knockdown in the
HFG group also resulted in a marked increase in
phosphoenolpyruvate carboxykinase (PEPCK) mRNA
and protein expression (Fig. 5B,D). Hepatic mRNA
expression of pyruvate carboxylase was significantly
lower in the NF group than in the HF and GFP
groups. However, hepatic pyruvate carboxylase
mRNA levels in the HFG group were similar to those
in the HF and GFP groups (Fig. 5E).
Effects of FGF-21 knockdown on the STAT3/
SOCS3 pathway
Recent in vivo studies have shown that STAT3 directly
targets the regulatory regions of both G6Pase and
PEPCK [17,19]. To determine whether the effect of
FGF-21 knockdown on insulin sensitivity was associ-
ated with changes in STAT3 signaling, we examined
the activation of STAT3 in the liver by western blot
analysis. HFD feeding in the HF and GFP groups
reduced phosphorylation of STAT3 in the liver
compared with SCD feeding in the NF group, and
FGF-21 knockdown in the HFG group further pro-
moted this reduction, suggesting that FGF-21 may
regulate STAT3 activation by directly phosphorylating
its tyrosine residues (Fig. 6A). Because one of the
transcriptional targets of STAT3 is SOCS3 [20], we
examined the SOCS3 mRNA and protein levels in
hepatic tissues of mice. As shown in Fig. 6B,C, SOCS3
mRNA and protein levels in the HFG group were
decreased to ~ 22% and 43% respectively, compared
to the HF and GFP groups (P < 0.05).
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Discussion
Recent reports have shown that FGF-21 participates in
the regulation of glucose homeostasis [21]. The lack of
mitogenic action makes this molecule an attractive can-
didate to treat type 2 diabetes and related metabolic
diseases. In a previous study, we showed that plasma
FGF-21 concentrations were significantly increased in
diabetic subjects [1]. Because diet-induced obese mice
have increased endogenous levels of FGF-21 and
respond poorly to exogenous FGF-21 [6], the elevation
of circulating FGF-21 in the subjects with type 2 diabe-
tes may be a compensatory response to the metabolic
stress imposed by obesity or type 2 diabetes. This phe-
nomenon is similar to hyperinsulinemia and hyperlep-
tinemia, in which the increased insulin and leptin
production is thought to compensate for the insulin
and leptin resistance associated with obesity.
Although FGF-21 has been reported to affect glu-
cose metabolism and insulin action, its effects on glu-
cose kinetics and insulin signaling, particularly the
STAT3/SOCS3 pathway, have not been systematically
examined. In this study, we have developed a mouse
model comprising adenovirus-mediated shRNA knock-
down of hepatic FGF-21. We demonstrated that use
of adenovirus-mediated shRNA against FGF-21
resulted in silencing of FGF-21 and some long-term
effects (up to 2 weeks), which allowed us to study the
metabolic impact of hepatic FGF-21 knockdown in an
insulin- resistance model (HFD-fed ApoE KO mice).
ApoE KO mice that develop severe hypercholester-
olemia and atherosclerosis on a SCD [22,23] are widely
used as a model for HFD-induced insulin resistance
[13,23,24]. In our study, the mice with FGF-21 knock-
down showed significant increases in blood glucose,
plasma insulin, FFA, lipid levels and hepatic TG com-
pared to controls. In addition, their GIR, an index of
glucose utilization, was decreased, whereas their HGP
was increased. Therefore, selective inhibition of FGF-
21 in the liver was sufficient to inhibit the effect of
insulin on lipolysis and glucose production. Further-
more, FGF-21 knockdown in Ad-shFGF-21-treated
mice led to a further decrease in the GIR, suggesting
lower glucose uptake and more serious insulin resis-
tance in the peripheral tissues of these animals.
We also examined the effect of FGF-21 knockdown
on glucose flux through G6Pase, the most distal step
in HGP. We found that, in HFD-fed mice, FGF-21
knockdown increased glucose flux through G6Pase
and glucose cycling. More importantly, we demon-
strated that the FGF-21 knockdown-mediated increase
in glucose production and G6Pase flux was due to
increases in glycogenolysis and gluconeogenesis. Con-
sistent with these results, FGF-21 knockdown mark-
edly increased hepatic G6Pase and PEPCK mRNA
and protein levels. However, FGF-21 knockdown had
little effect on the expression of pyruvate carboxylase,
another gluconeogenetic enzyme that catalyzes the car-
boxylation of pyruvate to oxaloacetate [25]. Pyruvate
carboxylase is exclusively expressed in mitochondria
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and contributes to de novo fatty acid synthesis by
providing oxaloacetate for conversion to citrate, which
is exported from the mitochondria and cleaved in the
cytosol to form oxaloacetate and acetyl CoA [26].
Thus, pyruvate carboxylase is apparently not essential
for gluconeogenesis. Therefore, it appears that the
effect of FGF-21 knockdown on gluconeogenesis is
mainly due to increased activation of hepatic G6Pase
and PEPCK.
It has previously been reported that STAT3 plays a
role in suppressing expression of gluconeogenic genes
[19,27]. To investigate the role of hepatic STAT3 sig-
naling in mediating the effect of FGF-21 knockdown
on HGP, we examined hepatic STAT3 phosphoryla-
tion in HFD-fed mice with FGF-21 knockdown. We
found that FGF-21 knockdown decreased the hepatic
phosphorylation of STAT3 in HFD-fed mice. This
finding provides support for the notion that FGF-21
knockdown modulates hepatic glucose homeostasis via
the STAT3 pathway, leading to hepatic activation of
G6Pase and PEPCK, and increased gluconeogenesis
and glycogenolysis. Our results are consistent with pre-
vious findings showing that STAT3 negatively regu-
lates gluconeogenic gene expression in vivo [17].
Recent studies have shown that SOCS3 is regulated
by the STAT pathway and various cytokines and hor-
mones, such as tumor necrosis factor a, interleukin-6,
resistin and adiponectin, all of which affect insulin sen-
sitivity [28,29]. It has also been reported that SOCS3
plays a role in the pathogenesis of insulin resistance by
integrating cytokine signaling with insulin signaling
[20]. To determine whether the insulin-desensitizing
effect of FGF-21 knockdown is related to SOCS3 sig-
naling, we examined the effect of FGF-21 knockdown
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frozen liver for the various groups.
Western blots and quantitative real-time
PCR were performed using pooled protein
and RNA extracts. (A) Relative G6Pase
mRNA expression. (B) Relative PEPCK
mRNA expression. (C) G6Pase protein
abundance. (D) PEPCK protein abundance.
(E) Relative pyruvate carboxylase (PC)
mRNA expression. NF, SCD-fed ApoE KO
mice; HF, HFD-fed ApoE KO mice; GFP,
HFD-fed ApoE KO mice treated with Ad-
shGFP; HFG, HFD-fed ApoE KO mice
treated with Ad-shFGF-21. Values are
means  SE from five independent
experiments, and are expressed as fold
changes relative to the levels in the NF
group.
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on SOCS3 expression in the liver. FGF-21 knockdown
induced decreases in SOCS3 mRNA and protein levels
in the liver of HFD-fed mice, associated with
decreased STAT3 activation and increased insulin
resistance. To date, the role of SOCS3 in insulin resis-
tance has remained controversial. Some studies have
reported a negative feedback relationship between
SOCS3 and insulin signaling (e.g. over-expression of
SOCS3 in liver caused insulin resistance, whereas sup-
pression of SOCS3 expression ameliorated insulin
resistance) [16,30], and others have shown a positive
relationship between SOCS3 and insulin action [31]. In
addition, over-expression of SOCS3 in adipose tissue
has been shown to inhibit insulin action but to system-
atically improve glucose metabolism under HFD con-
ditions [32]. In agreement with a previous study [31],
our results showed that the decrease of SOCS3
induced by FGF-21 knockdown in the liver increased
insulin resistance. However, it should also be noted
that the relationship between STAT3 and SOCS3
remains controversial. Ramadoss et al. [17] reported
that STAT3 serves as a positive regulator of SOCS3
expression, whereas others have shown that STAT3 is
a negative regulator of SOCS3 expression [16,29]. In
agreement with several previous studies, our results
showed that a decrease in STAT3 phosphorylation
accompanied by a decrease in SOCS3 expression,
induced by FGF-21 knockdown in the liver, further
promoted insulin resistance.
In conclusion, our findings suggest that FGF-21
knockdown in the liver increases gluconeogenesis and
glycogenolysis by activation of G6Pase and PEPCK
via the STAT3/SOCS3 pathway. This leads to exacer-
bated hepatic insulin resistance in HFD-fed ApoE KO
mice. These results provide in vivo evidence that the
insulin-sensitizing role of FGF-21 with respect to
changes in glucose flux is linked to the STAT3/SOCS3
pathway.
Experimental procedures
Construction and purification of adenoviruses
expressing shRNA against FGF-21
The adenoviral vectors that express shRNA against
FGF-21 were constructed as previously described [33,34].
The pAdxsi system (SinoGenoMax Co. Ltd, Beijing,
China) was used for shRNA construction. Briefly, two oli-
gonucleotides and complementary strands specific to mouse
FGF-21 were synthesized. The sequences were as follows:
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Fig. 6. Effects of FGF-21 knockdown on
liver SOCS3 expression and STAT3
activation. Total protein and RNA were
extracted from liver samples of mice.
Western blotting and real-time PCR
analyses were performed on pooled
protein and RNA extracts. (A) STAT3
phosphorylation. (B) Relative SOCS3
mRNA expression. (C) SOCS3 protein
abundance. NF, SCD-fed ApoE KO mice;
HF, HFD-fed ApoE KO mice; GFP, HFD-
fed ApoE KO mice treated with Ad-shGFP;
HFG, HFD-fed ApoE KO mice treated with
Ad-shFGF-21. Values are means  SE
from five independent experiments, and
are expressed as fold changes relative to
the levels in the NF group.
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sense 50-TTTGGGGTCTACCAAGCATACCCCATTCA
AGACGTGGGGTATGCTTGGTAGACCCTTTTTTG-30
and antisense 50-AGCTCAAAAAAGGGTCTACCAAG
CATACCCCACGTCTTGAATGGGGTATGCTTGGTAGA
-CCC-30. First, the annealed oligonucleotides were ligated
into the pSilencer1.2-U6 vector (Stratagene, Santa Clara,
CA, USA) and their sequences were verified. FGF-21
shRNA expression plasmids were transfected into 3T3-L
adipocytes, which were harvested 48 h later to test the effi-
ciency of these shRNA for FGF-21 knockdown. Second,
the selected pSilencer1.0-U6-shRNA plasmids were recom-
bined into the Gateway-based pAdxsi vector (Ad-shFGF-
21) to generate recombinant adenovirus vectors expressing
shRNA for FGF-21. A recombinant adenovirus vector that
expresses an shRNA against GFP (Ad-shGFP) was used as
a negative control. Finally, the recombinant adenoviruses
were amplified using HEK 293A cells, according to the
manufacturer’s instructions (Stratagene adenovirus amplifi-
cation kit, Stratagene), and a ViraBind adenovirus purifica-
tion kit (Cell Biolabs Inc., San Diego, CA, USA) was used
for large-scale amplification and purification of recombi-
nant adenoviruses according to the manufacturer’s instruc-
tions [35].
Mouse models and administration of
adenoviruses
To establish the insulin resistance model, male ApoE KO
mice at 3 weeks of age were obtained from the Experimental
Animal Center of Beijing University of Medical Sciences
(Beijing, China), acclimatized for a week, and fed with either
SCD (18% kcal from fat) or HFD (54% kcal from fat;
Research Diets Inc., New Brunswick, NJ, USA) for
16 weeks. Each mouse was separately housed in a tempera-
ture-controlled (24 °C) facility with a 12 h light/12 h dark
cycle (lights on at 22:00 h). SCD-fed ApoE KO mice (NF
group, n = 10) were used as diet controls. Twenty-six HFD-
fed ApoE KO mice were further divided into three groups,
and treated with 100 lL Ad-shFGF-21 (1 9 109 plaque-
forming units g1) (HFG group, n = 10), Ad-shGFP (GFP
group, n = 6) or sterile saline (HF group, n = 10). The ade-
noviruses expressing shGFP or shFGF-21 were injected into
mice through a tail vein at the end of both 14th and 15th
weeks of HFD feeding (Fig. 3A). As previously described
[36,37], 4 days before performing clamp experiments, the
mice were catheterized through the right jugular vein and the
left carotid artery under pentobarbital sedation (50 mgkg1;
Nembutal Abbott Laboratories, Abbott Park, IL, USA).
Catheters were placed subcutaneously, attached at the back
of the neck, and filled with heparinized saline. The jugular
and carotid catheters were used for blood sampling and infu-
sion, respectively. All studies were performed in accordance
with the guidelines for the use and care of laboratory animals
of the Chongqing Medical University Institutional Animal
Care and Use Committee.
Hyperinsulinemic/euglycemic clamps
To assess the effect of euglycemia/hyperinsulinemia on glu-
cose turnover, euglycemic/hyperinsulinemic clamps were
performed for 2 h after 7 days of adenoviral administration
as described previously [34,36]. Briefly, mice under chroni-
cally cannulated, conscious and unrestrained conditions
were fasted for 12 h before the studies. A bolus of insulin
(16 mU kg1) and [3-3H] glucose (5 lCikg1) was injected,
and thereafter insulin (Novo R, Novo Nordisk, Bagsvaerd,
Denmark, 5 mUkg1min1) was infused at a constant rate
throughout the clamp. [3-3H]-glucose was concomitantly
infused with insulin and 25% glucose via the carotid cathe-
ter at a rate of 0.1 lCikg1min1. Blood was sampled
from the jugular venous catheter every 10 min to determine
blood glucose concentration and to adjust the glucose infu-
sion rate to maintain blood glucose at its initial basal level
in each group. To determine the contribution of gluconeo-
genesis to the pool of hepatic glucose-6-phosphate, [U-14C]-
lactate (New England Nuclear, Boston, MA, USA; 20 lCi
bolus; 1.0 lCimin1) was administered to mice 10 min
before the end of the infusions. For determination of
plasma [3-3H] glucose concentrations, blood samples
(20 lL) were collected at 80, 90, 100 and 120 min after
starting the clamp experiments. For measurement of
plasma glucose, insulin, TG, TC, LDL-C, HDL-C and
FFA, additional blood samples (50 lL) were collected
before the start and at the end of the clamps. The ratio of
the glucose infusion rate to insulin was calculated as an
insulin sensitivity index in peripheral tissues. After comple-
tion of the clamp experiments, mice were anesthetized with
a sodium pentobarbital injection, the abdomen was quickly
opened, and portal vein blood was collected. Within 3 min,
hepatic tissues were harvested, frozen immediately using
liquid nitrogen-cooled aluminum blocks, and stored at
80 °C for subsequent analysis.
Analytical procedures
For determination of plasma [3-3H] glucose, plasma was
deproteinized with ZnSO4 and Ba(OH)2, dried to remove
H2O, resuspended in water, and counted in scintillation fluid
(Ultima Gold; Packard Instrument Co., Meriden, CT, USA).
After HPLC measurement of hepatic [14C]-phosphoenolpyr-
uvate and [3H/14C]-UDP-glucose specific activities the rates
of phosphoenolpyruvate gluconeogenesis were calculated.
The ratio of liver [3H] -UDP-glucose and plasma [3-3H] -glu-
cose-specific activities represents the percentage of the hepa-
tic glucose-6-phosphate pool directly derived from plasma
glucose (direct pathway). Gluconeogenesis was determined
from the specific activities of 14C-labeled hepatic UDP-glu-
cose (assumed to reflect the specific activity of hepatic glu-
cose-6-phosphate) and hepatic phosphoenolpyruvate
following infusion of [U-14C] -lactate and [3-3H] -glucose
using the formula: gluconeogenesis = total glucose
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output 9 [14C] -UDP-glucose specific activity/[14C]-phos-
phoenolpyruvate specific activity 9 2, as described elsewhere
[35]. Plasma insulin levels were determined using a commer-
cial insulin enzyme-linked immunosorbent assay kit (Diag-
nostic Products, Los Angeles, CA, USA), and the plasma
FFA level was determined spectrophotometrically using an
acyl CoA oxidase-based colorimetric kit (Wako Pure Chemi-
cal Industries, Osaka, Japan) [38]. The glucose oxidase
method was used for plasma glucose measurement. Plasma
TG, TC, HDL-C and LDL-C concentrations were measured
by the enzymatic colorimetric method (Sigma, St Louis, MO,
USA). Plasma FGF-21 levels were determined using an
ELISA kit (Phoenix Pharmaceuticals, Belmont, CA, USA).
Hepatic TG and glycogen levels were measured by a spectro-
photometric procedure as described previously [39,40].
Quantitative real-time PCR
Quantitative real-time PCR was performed as described
previously [33]. Briefly, muscle and hepatic tissue RNA was
isolated from frozen tissue (100 mg) using Trizol reagent
(Invitrogen, Carlsbad, CA, USA). Purified total RNAs
were used for cDNA synthesis using a PrimerScriptTM
reverse transcription reagent kit (Takara Bio Inc., Otsu,
Japan). Quantitative real-time PCR was performed using a
SYBR Green PCR kit (Takara Bio Inc.) and a Corbett
Rotor Gene 6000 real-time PCR system (Corbett Research,
Sydney, Australia). Expression of genes was analyzed by
the comparative Ct method, and normalized against that of
b-actin. The primer pairs used for quantitative real-time
PCR are listed in Table S1.
Western blot analysis
Western blot analysis was performed as described previously
[35]. Briefly, liver was homogenized in a solution of 20 mM
MOPS, 2 mM EGTA, 5 mM EDTA, 30 mM sodium fluoride,
40 mM b-glycerophosphate, 10 mM sodium pyrophosphate,
2 mM orthovanadate, 0.5% NP-40, and complete phospha-
tase inhibitor cocktail (Roche). Protein concentration was
determined using a BCA protein quantification kit (Pierce
Biotechnology, Rockford, IL, USA). Extracted proteins
were separated on either 4–12% Criterion XL (Bio-Rad,
Hercules, CA, USA) or 4–12% Bis-Tris NuPAGE (Invitro-
gen) gels, and blotted onto Immobilon FL poly(vinylidene
difluoride) membranes (Millipore, Billerica, MA, USA). The
films were blocked at room temperature for 1 h in Odyssey
blocking buffer (LI-COR Biosciences, Lincoln, NE, USA)
and incubated with primary antibodies against p-STAT3-
705 (Cell Signaling Technology, Beverly, MA, USA),
STAT3 (Santa Cruz Biotechnology Inc., Dallas, TX, USA),
FGF-21, SOCS3, G6Pase, PEPCK and b-actin (Research
Diagnostics Inc.) diluted 1 : 1000 in blocking buffer
(Tris-buffered saline/Tween-20) at 4 °C overnight. After
three washes with Tris-buffered saline/Tween-20 (0.1%), the
blots were incubated with horseradish peroxidase-conjugated
secondary antibodies (Invitrogen) (1 : 500 dilution) for 1 h
at room temperature. After two washes with Tris-buffered
saline/Tween-20 and a final wash with Tris-buffered saline
for 10 minutes at room temperature every time, the blots
were scanned using the Odyssey infrared imaging system
(LI-COR Biosciences), and the antigen–antibody complexes
were quantified using QUANTITY ONE analysis software (Bio-
Rad) as described previously [33].
Statistical analysis
Data are expressed as means  SE. Comparisons among
groups were performed by ANOVA, followed by a post hoc
least-squares difference test. Differences at P < 0.05 were
considered statistically significant. All data were statistically
analyzed using SPSS 13.0 (SPSS, Chicago, IL, USA).
Acknowledgements
This work was supported by research grants from the
National Natural Science Foundation of China
(81270913, 81070640, 81100567, 81300702, 81100567
and 81300670), the Doctoral Fund of the Ministry of
Education of China (20105503110002 and 2012550
3110003), the Natural Science Foundation Key Project
of CQ CSTC (cstc2012, jjB10022), and an American
Diabetes Association grant (number 1-10-CT-06) to
G.B.
References
1 Chen WW, Li L, Yang GY, Li K, Qi XY, Zhu W,
Tang Y, Liu H & Boden G (2007) Circulating FGF-21
levels in normal subjects and in newly diagnosed
patients with type 2 diabetes mellitus. Exp Clin
Endocrinol Diabetes 115, 1–4.
2 Li L, Yang G, Ning H, Yang M, Liu H & Chen W
(2008) Plasma FGF-21 levels in type 2 diabetic patients
with ketosis. Diabetes Res Clin Pract 82, 209–213.
3 Li K, Li L, Yang M, Zong H, Liu H & Yang G (2009)
Effects of rosiglitazone on fasting plasma fibroblast
growth factor-21 levels in patients with type 2 diabetes
mellitus. Eur J Endocrinol 161, 391–395.
4 Muise ES, Azzolina B, Kuo DW, El-Sherbeini M, Tan Y,
Yuan X, Mu J, Thompson JR, Berger JP & Wong KK
(2008) Adipose fibroblast growth factor 21 is up-
regulated by peroxisome proliferator-activated receptor c
and altered metabolic states.Mol Pharmacol 74, 403–412.
5 Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou
ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS,
et al. (2008) Serum FGF21 levels are increased in
FEBS Journal 281 (2014) 2136–2147 ª 2014 FEBS 2145
C. Wang et al. FGF-21 in hepatic gluconeogenesis and glycogenolysis
obesity and are independently associated with the
metabolic syndrome in humans. Diabetes 57, 1246–1253.
6 Fisher MF, Chui PC, Antonellis PJ, Bina HA,
Kharitonenkov A, Flier JS & Maratos- Flier E (2010)
Obesity is a fibroblast growth factor 21 (FGF21)-
resistant state. Diabetes 59, 2781–2789.
7 Kharitonenkov A, Shiyanova TL, Koester A, Ford
AM, Micanovic R, Galbreath EJ, Sandusky GE,
Hammond LJ, Moyers JS, Owens RA, et al. (2005)
FGF-21 as a novel metabolic regulator. J Clin Invest
115, 1627–1635.
8 Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu
CC, Chen Y, Moller DE & Kharitonenkov A (2008)
Fibroblast growth factor 21 corrects obesity in mice.
Endocrinology 149, 6018–6027.
9 Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits
G, Vonderfecht S, Hecht R, Li YS, Lindberg RA, et al.
(2009) Fibroblast growth factor 21 reverses hepatic
steatosis, increases energy expenditure, and improves
insulin sensitivity in diet-induced obese mice. Diabetes
58, 250–259.
10 Kharitonenkov A, Wroblewski VJ, Koester A, Chen
YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt
AB & Etgen GJ (2007) The metabolic state of diabetic
monkeys is regulated by fibroblast growth factor-21.
Endocrinology 148, 774–781.
11 Camporez JP, Jornayvaz FR, Petersen MC, Pesta D,
Guigni BA, Serr J, Zhang D, Kahn M, Samuel VT,
Jurczak MJ, et al. (2013) Cellular mechanisms by which
FGF21 improves insulin sensitivity in male mice.
Endocrinology 154, 3099–3109.
12 Gable D, Sanderson SC & Humphries SE (2007)
Genotypes, obesity and type 2 diabetes – can genetic
information motivate weight loss? A review. Clin Chem
Lab Med 45, 301–308.
13 Hansmann G, Wagner RA, Schellong S, Perez VA &
Urashima T (2007) Pulmonary arterial hypertension is
linked to insulin resistance and reversed by peroxisome
proliferator-activated receptor-c activation. Circulation
115, 1275–1284.
14 To AW, Ribe EM, Chuang TT, Schroeder JE &
Lovestone S (2011) The e3 and e4 alleles of human
APOE differentially affect tau phosphorylation in
hyperinsulinemic and pioglitazone-treated mice. PLoS
ONE 6, e16991.
15 Li L, Miao Z, Liu R, Yang M, Liu H & Yang G
(2011) Liraglutide prevents hypoadiponectinemia-
induced insulin resistance and alterations of gene
expression involved in glucose and lipid metabolism.
Mol Med 17, 1168–1178.
16 Kanatani Y, Usui I, Ishizuka K, Bukhari A, Fujisaka
S, Urakaze M, Haruta T, Kishimoto T, Naka T &
Kobayashi M (2007) Effects of pioglitazone on
suppressor of cytokine signaling 3 expression. Diabetes
56, 795–803.
17 Ramadoss P, Unger-Smith NE, Lam FS & Hollenberg
AN (2009) STAT3 targets the regulatory regions of
gluconeogenic genes in vivo. Mol Endocrinol 23, 827–
837.
18 Ling L, Gangyi Y, Shaochuan S, Mengliu Y, Hua L &
Boden G (2012) The effects of fibroblast growth factor-
21 knockdown and over-expression on its signaling
pathway and glucose-lipid metabolism in vitro. Mol Cell
Endocrinol 348, 21–26.
19 Inoue H, Ogawa W, Ozaki M, Haga S, Matsumoto M,
Furukawa K, Hashimoto N, Kido Y, Mori T, Sakaue
H, et al. (2004) Role of STAT-3 in regulation of
hepatic gluconeogenic genes and carbohydrate
metabolism in vivo. Nat Med 10, 168–174.
20 Howard JK, Flier JS, Howard JK & Flier JS (2006)
Attenuation of leptin and insulin signaling by SOCS
proteins. Trends Endocrinol Metab 17, 365–371.
21 Moller DE (2001) New drug targets for type 2 diabetes
and the metabolic syndrome. Nature 414, 821–827.
22 Breslow JL (1996) Mouse models of atherosclerosis.
Science 272, 685–688.
23 Zhang SH, Reddick RL, Piedrahita JA & Maeda N
(1992) Spontaneous hypercholesterolemia and arterial
lesions in mice lacking apolipoprotein E. Science 258,
468–471.
24 Chen Y, Yang G, Li L, Li K & Chen W (2009) The
changes of glucose-lipid metabolism in ApoE–/– mice
with high-fat induced insulin resistance. Chin J Diabetes
17, 590–592.
25 Utter MF & Keech DB (1963) Pyruvate carboxylase. I.
Nature of the reaction. J Biol Chem 238, 2603–2608.
26 Ballard FJ & Hanson RW (1967) The citrate cleavage
pathway and lipogenesis in rat adipose tissue:
replenishment of oxaloacetate. J Lipid Res 8, 73–79.
27 Inoue H, Ogawa W, Asakawa A, Okamoto Y,
Nishizawa A, Matsumoto M, Teshigawara K, Matsuki
Y, Watanabe E, Hiramatsu R, et al. (2006) Role of
hepatic STAT3 in brain-insulin action on hepatic
glucose production. Cell Metab 8, 3267–3275.
28 Uno T, He T, Usui I, Kanatani Y, Bukhari A, Fujisaka
S, Yamazaki Y, Suzuki H, Iwata M, Ishiki M, et al.
(2008) Long-term interleukin-1a treatment inhibits
insulin signaling via IL-6 production and SOCS3
expression in 3T3-L1 adipocytes. Horm Metab Res 40,
8–12.
29 Run-Zhe S, Feng Z, Fang W, De-Chun F, Xi-Hua L,
Wei-Hua R, Xiao-Lin W, Xue Y, Xiao-Dong L, Lei H,
et al. (2009) Adiponectin deficiency impairs liver
regeneration through attenuating STAT3
phosphorylation in mice. Lab Invest 89, 1043–1052.
30 Ueki K, Kondo T, Tseng YH & Kahn CR (2004)
Central role of suppressors of cytokine signaling
proteins in hepatic steatosis, insulin resistance, and the
metabolic syndrome in the mouse. Proc Natl Acad Sci
USA 10, 10422–10427.
2146 FEBS Journal 281 (2014) 2136–2147 ª 2014 FEBS
FGF-21 in hepatic gluconeogenesis and glycogenolysis C. Wang et al.
31 Torisu T, Sato N, Yoshiga D, Kobayashi T, Yoshioka
T, Mori H, Iida M & Yoshimura A (2007) The dual
function of hepatic SOCS3 in insulin resistance in vivo.
Genes Cells 12, 143–154.
32 Shi H, Cave B, Inouye K, Bjorbaek C & Flier JS (2006)
Overexpression of suppressor of cytokine signaling 3 in
adipose tissue causes local but not systemic insulin
resistance. Diabetes 55, 699–707.
33 Yang M, Zhang L, Wang C, Liu H, Boden G, Yang G
& Li L (2012) Liraglutide increases FGF-21 activity
and insulin sensitivity in high fat diet and adiponectin
knockdown induced insulin resistance. PLoS ONE 7,
e48392.
34 Sun B, Yang G, Yang M, Liu H, Boden G & Li L
(2012) Long-term high-fat diet links the regulation of
the insulin-sensitizing fibroblast growth factor-21 and
visfatin. Cytokine 59, 131–137.
35 Muse ED, Lam TK, Scherer PE & Rossetti L (2007)
Hypothalamic resistin induces hepatic insulin resistance.
J Clin Invest 117, 1670–1678.
36 Ling L, Gangyi Y, Shaochuan S, Mengliu Y, Hua L &
Boden G (2009) The adipose triglyceride lipase,
adiponectin and visfatin are downregulated by tumor
necrosis factor-a (TNF-a) in vivo. Cytokine 45, 12–19.
37 Qin S, Ling L, Renzhe L, Mengliu Y, Hua L & Gangyi
Y (2009) Overexpression of visfatin/PBEF/Nampt alters
whole-body insulin sensitivity and lipid profile in rats.
Ann Med 41, 311–320.
38 Zhang L, Yang M, Ren H, Hu H, Boden G, Li L &
Yang G (2013) GLP-1 analogue prevents NAFLD in
ApoE KO mice with diet and Acrp30 knockdown by
inhibiting c-JNK. Liver Int 33, 794–804.
39 Ramesha CS, Paul R & Ganguly J (1980) Effect of
dietary unsaturated oils on the biosynthesis of
cholesterol, and on biliary and fecal excretion of
cholesterol and bile acids in rats. J Nutr 110, 2149–2158.
40 Ferre T, Riu E, Bosch F & Valera A (1996) Evidence
from transgenic mice that glucokinase is rate limiting
for glucose utilization in the liver. FASEB J 10, 1213–
1218.
Supporting information
Additional supporting information may be found in
the online version of this article at the publisher’s web
site:
Fig. S1. Relative FGF-21 mRNA levels in the skeletal
muscle of ApoE KO mice.
Fig. S2. Plasma glucose levels and glucose disposal
rate during hyperinsulinemic/euglycemic clamping.
Table S1. Primers used for real-time PCR analysis.
FEBS Journal 281 (2014) 2136–2147 ª 2014 FEBS 2147
C. Wang et al. FGF-21 in hepatic gluconeogenesis and glycogenolysis
